XOMA (XOMA) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.DATEWednesday, March 18, 2026 at 8:00 a.m. ETCALL PARTICIPANTSChief Executive Officer — Owen HughesChief Investment Officer…
0,154€
2,67%
Echtzeit-Aktienkurs Gossamer Bio Inc.
Bid:
Ask:
Nachrichten zur Gossamer Bio Inc. Aktie
GOSS DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action – GOSS
NEW YORK, May 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
Gossamer Bio, Inc. (GOSS) Q1 2026 Earnings Call Transcript
…
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of -17.65% and +181.04%, respectively, for the quarter ended March 2026. Do…
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
NEW YORK, May 10, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…
Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of -7.14% and +81.52%, respectively, for the quarter ended December 2025. Do…
Gossamer Bio: UBS hebt Einschätzung und Kursziel an - Erfolgswahrscheinlichkeit von Seralutinib wird gemäß des Analysten unterschätzt
Gossamer Bio Inc. (GOSS) positioniert sich als ein Unternehmen, das sich auf die Entwicklung und Kommerzialisierung innovativer Therapien für pulmonale…
Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of +5.56% and +155.88%, respectively, for the quarter ended June 2025. Do…
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of 11.11% and 167.27%, respectively, for the quarter ended March 2025. Do…
Gossamer Bio shares rise on Q4 earnings beat By Investing.com
Gossamer Bio shares rise on Q4 earnings beat…
Gossamer Bio (GOSS) Reports Q4 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of 11.76% and 19.63%, respectively, for the quarter ended December 2024. Do…
Gossamer Bio Inc Aktie: Optimismus treibt Kurs!
Die Gossamer Bio Inc zeigt zu Beginn des Jahres 2025 eine beachtliche Entwicklung an den Märkten. Der aktuelle Kurs der…
Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss
…
Gossamer Bio a new outperform at Oppenheimer on seralutinib for PAH
…
Gossamer Bio executive sells over $5,000 in company stock By Investing.com
Gossamer Bio executive sells over $5,000 in company stock…
Gossamer Bio expands board with medical and financial experts By Investing.com
Gossamer Bio expands board with medical and financial experts…